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In this issue of the Journal of Thoracic Oncology, Masters et al.1 present the results ofa randomized phase II trial evaluating two schedules of gemcitabine and carboplatin in
patients with advanced non–small-cell lung cancer using a “selection design.” Assuming
a hazard rate of 1.2 for progression-free survival, the authors state that a sample of 50
patients per arm provided at least an 80% chance of picking the correct regimen using a
one-sided log rank test. Unfortunately, the statistical section is rather brief, with no
references cited for the selection design used; hence, the exact calculations could not be
verified. This is not uncommon in the literature; only 60 of the 266 randomized phase II
trials included in a recent literature review had an identifiable statistical design section.2
Given the recent increased interest in randomized phase II trials, driven primarily by the
need to evaluate the efficacy of multiple regimens concurrently, a detailed description of
the design, conduct, analysis, and interpretation of the trial results is vital to assess the
scientific merits and improve our understanding of these designs. We present some of the
nuances of a randomized selection design (also known as a screening or pick the winner
design).
The primary purpose of phase II clinical trials in cancer is to identify promising
regimens to take forward to a larger phase III trial. Evaluating regimens by comparing
outcomes among independent single-arm trials is problematic because of the confounding
effects of trial outcomes with “unknown” trial effects such as patient selection, referral
bias, and differences in supportive or ancillary care. Randomization in phase II studies is
one method to reduce such outcome-trial effect confounding.3 For cases in which there
may be several promising regimens/schedules/treatments for a patient population, a
randomized selection or screening design can be used to select the most promising
treatment to be further tested. In this setting, controlling type I error (false positive) is less
relevant than controlling type II error (false negative), as the goal of such trials is to ensure
that if one regimen is indeed superior, then there is a high probability that it will be
selected. Screening designs are designed to make a selection between promising experi-
mental regimens in a phase II setting and therefore should not typically include the
standard of care or control arm.4 In other words, screening trials are underpowered for
performing formal hypothesis testing or comparisons of endpoints, both primary and
secondary, across selection arms. Although commonly reported in published studies,
including that of Masters et al.,1 p values based on formal statistical tests of comparisons
from selection designs are incorrect and should be avoided.2
The selection of an experimental treatment in a screening design can be based solely
on the primary endpoint, or it can include other factors when the observed difference in
the primary outcome is deemed small.3–5 The latter is known as a flexible screening
design, in which other factors such as toxicity, cost, convenience, or quality of life are
taken into consideration in making the selection in addition to the primary efficacy
measure, much as in clinical practice.4 The wealth of opportunities in cancer drug
development mandates intelligent clinical trial design. In our opinion, phase II randomized
screening trials, when properly applied, can assure optimal use of limited phase III
financial and patient resources.
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